Related Experiment Video
Updated: Mar 31, 2026
06:10
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
Published on: March 30, 2020
8.5K
Fusion Proteins: Aflibercept (VEGF Trap-Eye)
Developments in Ophthalmology
|October 27, 2015
Summary
Aflibercept, a novel vascular endothelial growth factor (VEGF) inhibitor, acts as a cytokine trap to block VEGF. This innovative biologic offers a new therapeutic approach for managing retinal vascular diseases.
Area of Science:
- Ophthalmology
- Molecular Biology
- Immunology
Background:
- Current treatments for retinal diseases involve VEGF inhibitors like antibodies and aptamers.
- Cytokine traps represent an alternative strategy for VEGF blockade in retinal conditions.
Purpose of the Study:
- To summarize the chemical properties of aflibercept.
- To review studies demonstrating aflibercept's efficacy in treating retinal vascular diseases.
Main Methods:
- Aflibercept is a soluble fusion protein combining VEGF receptor (VEGFR)-1 and VEGFR-2 extracellular domains with human IgG Fc.
- Its design minimizes immunogenicity by using all human amino acid sequences.
Main Results:
- Aflibercept has shown a role in managing neovascular age-related macular degeneration.
- Studies support its use in diabetic retinopathy, macular edema, and retinal vein occlusion.
Conclusions:
- Aflibercept functions as a cytokine trap, offering a novel mechanism for VEGF inhibition.
- It presents a promising therapeutic option for various sight-threatening retinal vascular diseases.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K